+ Site Statistics
References:
54,258,434
Abstracts:
29,560,870
PMIDs:
28,072,757
+ Search Articles
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ PDF Full Text
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Translate
+ Recently Requested

Statin use and the risk of developing diabetes: a network meta-analysis



Statin use and the risk of developing diabetes: a network meta-analysis



Pharmacoepidemiology and Drug Safety 25(10): 1131-1149



Randomized controlled trials have shown mixed findings regarding the association of statins and diabetes. This systematic literature review and network meta-analysis (NMA) was performed to update evidence on this association to possibly assist clinicians in making more informed treatment choices. We identified studies relevant to our NMA by performing study searches in databases like Embase, Cochrane, and PubMed, published between August 2010 and June 2014. Pre-2010 studies were identified from bibliography of previously published meta-analyses. Unpublished study data were found from clinicaltrial.gov. Data synthesis was performed by pairwise meta-analysis and NMA within a Frequentist framework. Twenty nine trials in which 1 63 039 participants had been randomized were included in this review; among these 1 41 863 were non-diabetic patients. The direct meta-analysis showed that statins, as a class, significantly increased the likelihood of developing diabetes by 12% (pooled OR 1.12; 95%CI 1.05-1.21; I2 36%; p = 0.002; 18 RCTs). In the NMA, atorvastatin 80 mg was associated with a highest risk of diabetes, with OR of 1.34 (95%CI 1.14-1.57) followed by rosuvastatin (OR: 1.17; 95%CI: 1.02-1.35). The ORs (95%CIs) for simvastatin 80 mg, simvastatin, atorvastatin, pravastatin, lovastatin and pitavastatin were 1.21 (0.99-1.49), 1.13 (0.99-1.29), 1.13 (0.94-1.34), 1.04 (0.93-1.16), 0.98 (0.69-1.38) and 0.74 (0.31-1.77), respectively. High-dose atorvastatin increased the odds of developing diabetes even when compared with pravastatin, simvastatin and low-dose atorvastatin in the NMA. Based on the results, statins, as a class, increased the risk of diabetes significantly in the pairwise meta-analysis. Overall, there appears to be a small increased risk of incident diabetes, particularly with more intensive statin therapy, although more data would be valuable to increase the robustness of this interpretation, given that the lower confidence intervals of our study analyses are close to, or just crossing one. Copyright © 2016 John Wiley & Sons, Ltd.

(PDF emailed within 0-6 h: $19.90)

Accession: 058900518

Download citation: RISBibTeXText

PMID: 27277934

DOI: 10.1002/pds.4020


Related references

Statin therapy and risk of developing type 2 diabetes: a meta-analysis. Diabetes Care 32(10): 1924-1929, 2009

Statin Use And Risk Of Developing Diabetes In Cardiovascular Disease: Systematic Literature Review And Meta-Analysis. Value in Health 17(7): A478, 2014

Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials. Lancet 375(9716): 735-742, 2010

Lower intensified target LDL-c level of statin therapy results in a higher risk of incident diabetes: a meta-analysis. Plos One 9(8): E104922, 2016

Risk of incident diabetes with intensive-dose compared with moderate-dose statin therapy: a meta-analysis. JAMA 305(24): 2556-2564, 2011

Bilateral Earlobe Crease as a Marker of Premature Coronary Artery Disease. Cureus 10(5): E2616, 2018

A meta-analysis of passive smoking and risk of developing Type 2 Diabetes Mellitus. Diabetes Research and Clinical Practice 107(1): 9-14, 2015

Statin use and the risk of developing diabetes. Study confirms a link, but does the risk outweigh the benefits?. Johns Hopkins Medical Letter Health After 50 24(2): 1-2, 2012

Definitions of Metabolic Health and Risk of Future Type 2 Diabetes in BMI Categories: A Systematic Review and Network Meta-analysis. Diabetes Care 38(11): 2177-2187, 2016

The effect of day care exposure on the risk of developing type 1 diabetes: a meta-analysis of case-control studies. Diabetes Care 24(8): 1353-1358, 2001

Thiazolidinediones and risk of heart failure in patients with or at high risk of type 2 diabetes mellitus: a meta-analysis and meta-regression analysis of placebo-controlled randomized clinical trials. American Journal of Cardiovascular Drugs 11(2): 115-128, 2012

Statin use and risk of fracture: a meta-analysis. International Journal of Clinical and Experimental Medicine 8(5): 8269-8275, 2015

Efficacy and safety of statin treatment for cardiovascular disease: a network meta-analysis of 170,255 patients from 76 randomized trials. Qjm 104(2): 109-124, 2011

Primary prevention of cardiovascular mortality and events with statin treatments: a network meta-analysis involving more than 65,000 patients. Journal of the American College of Cardiology 52(22): 1769-1781, 2008

Extending methods for investigating the relationship between treatment effect and baseline risk from pairwise meta-analysis to network meta-analysis. Statistics in Medicine 32(5): 752-771, 2013